TW200812594A - Medicine for prevention of and/or recovery from fatigue - Google Patents

Abstract

The present invention provides a medicament having an excellent effect of preventing and/or relieving physical fatigue and/or mental fatigue. The present invention also provides a medicament for preventing and/or relieving fatigue, which contains adenosine 5'-triphosphate or a physiologically acceptable salt thereof and a processed garlic product in combination.

Description

200812594 IX. INSTRUCTION DESCRIPTION OF THE INVENTION [Technical Field] The present invention relates to a medicine having a preventive and/or palliative effect on physical fatigue and/or mental fatigue. [Prior Art] In recent years, the number of people suffering from fatigue is gradually increasing. Fatigue is defined as "a temporary state of decline in functional ability as a result of physical or mental activity" and is usually classified as physical fatigue and mental fatigue.

Fatigue not only reduces QOL (quality of life), but also causes immunity, which leads to unexpected diseases, etc. Therefore, the current situation is that the industry expects k to provide a medicine with excellent fatigue alleviation. 5 A compound of the acid gland that has an energy phosphate bond and has a large amount of energy released when hydrolyzed into 5'-adenosine diphosphate (ADp) and phosphoric acid. Because of its nature, adenosine triphosphate is widely associated with the metabolism of saccharides, fats, or proteins as a phosphate donor. The energy produced by the hydrolysis of adenosine triphosphate becomes an energy-requiring reaction in the organism. driving force. Regarding the 5,-triphosphate material as a medical material, the following medicines are currently used: for the sequelae of head trauma, _ dysfunction, and the regulation of the regulation of visual fatigue, the chronic inflammation of the digestive tract can be seen. Intestinal ingots or granules are administered orally in 4 〇~6 〇, (1), and for gerax caused by Meniere's disease and by inner ear disorders, twice with 100 mg, 3 times a day. In addition, p-five, one-pronged, combined with adenosine 51-triphosphate and vitamin B1 bamboo organisms ’ cheng’s business has a therapeutic effect on visual fatigue (patent: 1220J2.doc 200812594)}. Further, a method of reducing muscle fatigue by administering a gem of 5,-triphosphate is known (Patent Document 2). On the other hand, it has been found that garlic processed products such as dried powder extracted from garlic have strong effects such as strongness, stomach, intestines, and fatigue alleviation. For example, it is known that: it has a tonifying agent and a mash as a garlic processing product. _ heart and other nourishing strong biopharmaceuticals as a characteristic liquid preparation (Patent Document 3); - species (&) as a large: one or more of the processing materials, such as x〇amidin, nourish and strong. (b) a preparation selected from the group consisting of vitamins, nicotinic amide, biotin, citrate lysine, ubiquinone and caffeine, and (4) stevioside. The ratio of the bitterness of the bitterness in the preparation to the content of the stevioside is, in the range of 1 part by weight of the bitter component, and the range of the sweetness is _g parts to G1 parts by weight, which is characterized by the nourishing and strong preparation of the crude drug ( Patent Document 4); a nourishing strongener containing black flax, black soybean, kelp, green tea, dry sweet, rice germ, dried garlic as a garlic processing product, and A1Ge arbGreseens as essential characteristics of age (patent text 5); comprises benfotiamine (fotiamine) and the workpiece as the garlic asthenopia improving agent (Patent Document 6). However, none of the above-mentioned prior art teaches or indicates that a synergistic effect against prevention and/or alleviation of fatigue is produced by combining adenosine 5 or a physiologically acceptable salt with a garlic processed product. [Patent Document 1] Japanese Laid-Open Patent Publication No. Hei. No. Hei. No. Hei. No. Hei. No. Hei. No. Hei. [Patent Document 5] Japanese Patent Laid-Open Publication No. Hei. No. 2002-275071 [Patent Document 6] Japanese Patent Laid-Open Publication No. 2002-275071 The object of the present invention is to provide a new type of medicine which has a preventive and/or palliative effect on physical fatigue and/or mental fatigue.

[Means for Solving the Problems] As a result of intensive studies to solve the above problems, the inventors have unexpectedly found that significant prevention has been found by using 5'-ATP or a physiologically acceptable salt thereof in combination with a garlic processed product. And/or alleviating the fatigue effect, the synergistic prevention and/or mitigation of the fatigue effect can be achieved as compared with the case of using it alone, thereby completing the present invention. That is, a medicine for preventing and/or alleviating fatigue, a combination of adenosine citrate or a physiologically acceptable salt thereof and a garlic processed product is provided. Further, the present invention provides a drug for adenosine triphosphate or a processed product of garlic and a mixture of garlic and a used food. Further, the present invention provides a method for preventing and/or continuation of #&#拉料*执·里顶一方和/次缓缓疲劳, and ';• administering an effective amount of 5,- Sanshi phthalate adenosine #甘# " Salt and garlic processed. "Growth money and its physiology" [Effects of the invention] The present invention, Yun Yun, Shan # c ^ ..., due to the synergistic effect of 5 - adenosine monophosphate or its physiological and scientific processing, has a a 勹 1 branch Preventive and/or; 1220l2.doc 200812594 Relieve fatigue and prevent and/or alleviate effects. ^乡和' or mental fatigue exerts excellent [Embodiment] The invention of the present invention #μ 西梁系 Prevent and / or alleviate the filling or its physiology:: The system is 5 - 2, the medical system prevention and treatment of the present invention / Wide processing materials combined. Sanqing* or his physiologist changed the time to vote. The garlic processed product is simultaneously administered or the medicine of the present invention is used as a combination of a morphological preparation and a morphological preparation (set) which allows for the adenosine diphosphate or its physiological orphan. The unit dosage of the substance or the physiology of the salt plate is allowed to be larger than the unit dosage form of the medicinal planting 铷A /, the large-scale processing material, and 5 things are provided. Further, the physiology of the sputum + 1 and sputum is provided by a composition containing 5,-triphosphate adenosine 4 /, a salt-tolerant salt hydrazine composition. A medicine for administering a form to a unit of a processed material. The medicine used in the medicine of the present invention is a substance which is known as a substance, and which is acceptable to the manufacturer. Material, a... The physiology of adenosine allows the bee's sputum, Λ 5 - diphosphate · Lift: face Lai, # Β is not particularly limited, such as can be listed, soda potassium and other alkali metal salts; magnesium 2S, calcium Among them, Bi预防 prevents the prevention of bauxite metal salts. Good is t-sodium diphosphate. In particular, the formulation of the salt allowed has been... The sacral sacral ridge or its physiology city' therefore provides the invention according to the use of a single, five-squamous gland: salt preparation... In the case of the commercially available J22012.doc 200812594, it is also possible to use a formulation containing 5·-san Miyu or its physiologically acceptable salt. For example, "ADETPHOS" (Hinghe Co., Ltd.) is sold. There is no particular restriction on the type of "garlic processed" used in this month's peony. Anyone who uses the right root of the allium sativum can be used. In the present specification, the term "plus =" means that the raw garlic is subjected to heating, drying, pulverizing, or extracting, and the like, but the type of processing is not particularly limited.

, ····························································································· Treatment, or heating of raw garlic; etc.; especially good extraction with water-soluble machine solvent: > + : field _, stroke treatment. Examples of the oil to be used for the blood pumping include edible vegetable oils such as seed oil, eucalyptus oil, and soybean oil; and examples of the water-soluble organic solvent include lower alcohols such as ethanol or isopropyl alcohol, or: A glycol such as an alcohol or diethylene glycol. As for the garlic processed product, the viewpoint of preventing and/or alleviating the fatigue effect e, for example, 'it is better to process garlic, garlic extract, garlic extract, or dry * stay big, etc., and the good one is to process garlic. . Processing garlic, ~ 曰 曰 加热 加热 加热 加热 加热 加热 加热 加热 加热 加热 加热 加热 加热 加热 加热 大蒜 大蒜 大蒜 大蒜 大蒜 大蒜 大蒜 大蒜 大蒜 大蒜 大蒜 大蒜 大蒜 大蒜 大蒜 大蒜 大蒜 大蒜 大蒜 大蒜 大蒜 大蒜 大蒜 大蒜 大蒜 大蒜 或 或 或 或 或 或 或 或 或Ox), oxoamidin (registered trademark) 扣 ( (manufactured by Riken Chemical Industry Co., Ltd.), oxorediiin (registered trademark) (manufactured by Riken Chemical Industry Co., Ltd.), or 〇x〇reduin (registered trademark) powder (Liyan Chemical Industry Co., Ltd.) Ltd.) and so on. As for garlic extraction, 122012.doc -10- 200812594, for example, commercially available: 4 # • Garlic extract (made by Alps Pharmaceutical Industry Co., Ltd.) or garlic dip 暮Γ (made by Japan Powder Pharmaceutical Co., Ltd.). As for dry garlic, for example, I · 叩〇: Garlic Powder (Liyan Chemical Industry)

Co., Ltd., Luo H, 3XK〇ast Garlic Powder EX (Liyan Chemical Industry Co., Ltd., Chu ^ i) won. Among these garlic processed products, 〇X〇_dm (&trademark) (manufactured by Riken Chemical Industry Co., Ltd.), 〇 (registered trademark) powder (Liyan Chemical Industry Co., Ltd.)

| ) , redUm (5 main volume trademark) (manufactured by Riken Chemical Industry Co., Ltd.) or 〇Xoreduin (registered trademark) powder (manufactured by Riken Chemical Industry Co., Ltd.). In the pharmaceutical of the present invention, the ratio of the combination of the gallium phosphate and the physiologically acceptable salt to the U-processed material is not particularly limited, and the manufacturer can appropriately select it according to the test method specifically disclosed in the following examples. In the present invention, for example, when using: n garlic as a garlic processed product, in view of preventing and/or alleviating the synergistic effect of the fatigue composition, the salt is allowed relative to 5, octanoic acid or its physiological property. ! The mass part is preferably in the range of 6 to 34 parts by mass, more preferably in the range of GG12 to 17f, more preferably in the range of 6 to 3.4 parts by mass, more preferably The processed garlic is used in the range of 1 to 2 parts by mass, particularly preferably in the range of 0.12 to 0.42 parts by mass. Further, in the case of using other garlic processed materials, from the viewpoint of preventing and/or alleviating the synergistic effect of the fatigue action, it is preferred that the adenosine triphosphate or the physiologically acceptable salt 丨 mass portion thereof is In terms of the amount of the raw material, it is in the range of 12 to 3400 parts by mass, more preferably in the range of 24 to n = parts by mass, more preferably (range of M2 to 34 G parts by mass, better) It is used in the range of 0.24 to 0.48 parts by mass of the I&, particularly preferably 0.24 to 0.48 parts by mass. In the medicine for preventing and/or alleviating fatigue of the present invention, in addition to 5, adenosine triphosphate or For the purpose of enhancing the prevention and/or alleviation of fatigue in addition to the salt and the processed garlic, it is preferred to further mix vitamin B. As for vitamin B, for example, vitamin B, hydrochloric acid is mentioned. Sulfur • Amine, thiamine nitrate, dithiamine nitrate, thiamine disulfide, thiamine, bisphosphonium sulphate, sodium salt, and Dicethiamine hydrochloride

Hydrochloride), fursultiamine hydrochloride, 奥ct〇tiamine, cyc〇tiamine, bisibmhiamine, bisbentiamine, fursultiamine, propyl sulphide Pr〇suitiamine), benfamine, etc.; vitamins & glycerol adenine, sodium riboflavin, riboflavin phosphate For example, pyridoxine hydrochloride (pyrid〇xine), pyridoxal phosphate (Pyrid〇Xal), etc.; vitamins, hydroxycobalamin hydrochloride, hydroxycobalamin, cyanocobalamin, hydroxycobalamin, methylcobalt Amine (mec〇balamin) and the like. In the present invention, in terms of the synergistic effect of preventing and/or alleviating the fatigue action, it is preferred to blend one or more selected from the group consisting of vitamins, vitamins & vitamins, vitamins, and vitamins. Vitamin B, more preferably formulated into two or more kinds of vitamin B selected from the group consisting of vitamin B1, vitamins & vitamins and vitamins, and more preferably formulated into vitamins Β, vitamin I, vitamins & More than 3 kinds of vitamin B in 2] 2, especially good combination of vitamins, vitamins & vitamins 122012.doc -12- 200812594 B 6 and vitamin B 1 2 . In the pharmaceutical of the present invention, the ratio of the combination of the salt of the triterpenoids or the physiologically acceptable salt and the vitamin B is not particularly limited, and from the viewpoint of preventing and/or alleviating the synergistic effect of the fatigue action, for example, In the case of 5, triphosphate = 1 part by mass of the physiologically acceptable salt, it is preferred to use vitamin B in the range of _ 20 parts by mass, preferably 0.003 to 2 parts by mass. 8 parts by mass, preferably _~ 〇 δ mass parts of the range ^ 吏 use vitamin Β 2, 〇 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _3 to Q 3 parts by mass, and preferably 0._003 to 0. 03 parts by mass of vitamins are used. As the medicine of the present invention, it may be any one suitable for oral administration or 2 medicines suitable for: Shikou technique and medicine, and preferably suitable for oral administration.

medicine. ^ V ▲: It is suitable for oral administration of medicine. What is better, as a solid unit in the form of solid unit injection and containing y·three-disc acid or its physiologically acceptable salt and garlic processing, Provided in the form of a solid or liquid pharmaceutical composition. When the medicine of the present invention is provided as a medicine suitable for oral administration or a medicine suitable for π-injection*, there is no particular limitation on the form of administration thereof. For example, a pharmaceutical composition in a solid form such as a powder, a granule, a lozenge, a chewable tablet, a film-coated tablet, a sugar-coated soft capsule, or a hard capsule, a beverage: a pharmaceutical composition in the form of a bath, or In the semi-solid form of the jelly or the like: any one of the composition of the music. In the present invention, it is particularly preferable to form the solid form of the medical music H in terms of stability and susceptibility. When the pharmaceutical composition of the present invention is provided as a pharmaceutical composition containing 5|_ adenosine triphosphate or a physiologically acceptable salt thereof and a processed product of garlic 122012.doc 200812594, there is no particular limitation on the pharmaceutical composition: It can be determined based on the above-mentioned, and a ratio, depending on the form of the doctor's advice and the composition. For example, when it is provided as a solid form of the medicine climbing composition, it is used in the N-shaped daily keeper of the processing agent, which is widely used as a garlic processing material, and can be adjusted into 1 to 30G per unit of the pharmaceutical composition. About 5 mg of triphosphonate-fee gland or its physiologically acceptable salt, processing cup of about 1~3 00 mg, in addition to 5,-triphosphate gland or

When the physiology allows salt, death, and ring-shaped processing, and then blends into vitamin B, for example, vitamin B can be added to each of the early mornings, and 0.5 to 50 mg can be added. Vitamins b...~(10) are called vitamin B6, G._3~1'5哗, and vitamin B丨2. In the prevention and/or mitigation of the stagnation waste of the present invention, it may be appropriately formulated into 5'-diphosphonium perindole, a Hi adenosine or a physiologically acceptable salt thereof, and a garlic processing product, depending on the purpose of the preparation. 'And vitamin B,. Bu, living as B2, vitamin Βό, vitamin b】 2 and other ingredients other than vitamin B. 5 As for such ingredients, vitamin A, water, gluten, miscellaneous worms, /, probiotics D, vitamin E, vitamins, shellfish, caffeine, amino acids, liver disease Medication, raw medicine, other ingredients, etc. ',', and vitamin A' may be exemplified by retinyl acetate, retinyl palmitate, vitamin A oil, liver oil, and strong liver oil. As for water, a combination of vitamins, ascorbic acid, ascorbic acid, sodium ascorbate, nicotinic acid, nicotinamide, alcohol, calcium pantothenate, sodium pantothenate, panthenol, biotin, folic acid, etc. . As for vitamin D, ergocalcif (10) 1 , 122012.doc -14- 200812594 cholecalciferol, and the like can be mentioned. As for vitamin E, succinic acid d_a_tocopherol, succinic acid dl_α·tocopherol, dl-a-tocopheryl calcium succinate, acetic acid heart tocopherol, acetic acid dl-a-shengyue, da-fertility @分, dl-a- fertility scores, etc. As for the vitamin-like substance, inositol, physicohexadecanoate, orotic acid, choline orotate, gluten, tlnoctic acid, lipoic acid (thi) 〇ctic acid amide), carnitine chloride, ubidecarenone, choline bitartrate, rutin, and the like. As the mineral, there may be mentioned calcium citrate, calcium glycerate phosphate, sodium gluconate, magnesium carbonate, calcium carbonate, calcium gluconate, precipitated calcium carbonate, calcium lactate, anhydrous calcium hydrogen phosphate, calcium hydrogen phosphate, sodium chondroitin sulfate. Wait. As for caffeine, in addition to caffeine, caffeine derivatives such as anhydrous caffeine and sodium caffeine can be cited. As for the amino acid, it can be exemplified by: L_夭夂妒...pure τ days; fe & L, L-aspartic potassium citrate, L-aspartic acid sodium, L-day long g5 face miscellaneous τ , I fo acid magnesium, L-hydrochloric acid cysteine, L-cysteine, amino acetic acid, iso-leucine, arginine hydrochloride, lysine hydrochloride, aminic acid, L-threonine, L_ citrulline dehistamine hydrochloride, L-leucine, DL-methylthiazide τ #二a τ claw% L, L-phenylalanine, L_tryptophan, and the like. As for the liver disease medication, there are mentioned: ursodesoxycholic acid, dehydrocholic acid, "(3)-1C acid), _uronic acid lactone, glucuronic acid, glucitol Acid amide, —# 夂 夂 夂 夂 、 、 、 胺 胺 胺 胺 胺 胺 、 、 、 、 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 15- 200812594 As for raw medicine, categorize: catechu, fennel, thorn Wuzhi, Guarana (g job name, licorice, material, cinnamon, saffron, hawthorn, yam, peony, amomum, ginger, female贞二, broadcast, jujube, clove, dried tangerine peel, angelica, rabbit silk, 牛牛〆人蔘, 茯 、, Brazilian 榥榥木 '木香, puzzle..., meat chain 蓉, royal jelly, antler, etc. For example, a placenta or the like may be mentioned as the medicine of the present invention. The medicine of the present invention can be suitably prepared according to the method conventionally used in the industry. In this case, ι or 2 can be used as needed. Additive for preparation. As for additive for preparation, example = column: 嚷V. Adhesion The agent, the disintegrant, the lubricant, the colored second M coating agent, etc., but are not limited thereto. w Sugar, sweet „: exemplified by lactose, starch, 'crystalline cellulose, strict reading, or light weight Anhydrous material, etc. As for the binder, it can be listed as di-propylmethylcellulose, propylcellulose, gelatin, alpha-dioxide: ethylene, ethyl, or etoluene ). As the detoxifying agent, carboxymethylcellulose fiber, crosslinked methine cellulose, cross-linked polystyrene powder, or low-substituted hydroxypropylcellulose may be mentioned. As the lubricant, magnesium stearate or talc powder may be mentioned. As the coloring agent, tar pigment or ferric oxide or the like can be cited. As the flavoring agent, there may be mentioned: stevia;: 4 bar of sweetness, or a fragrance or the like. As the coating agent, 绫 methyl ethyl cellulose, phenyl phthalate H cellulose, methyl acrylate acrylic acid copolymer L, methacrylic acid copolymer 1 , hydroxypropyl 122012.doc -16- 200812594 Methyl cellulose phthalate, about the work of Zeng " propyl methyl ketone acetate amber phthalate and other film-forming polymers. In addition, open y film formation, can also be blended into lemon dimethoate, triacetin, -., the main one 匕 乙 一 予 special plasticizer, talcum powder, milk page color Powders such as ferric oxide, ferric oxide, legal pigments, light anhydrous citric acid, and aqueous cerium oxide. The dosage form of the medicine of the present invention and the degree of the applicable symptoms can be appropriately selected according to various conditions such as medicine, n M, s A + / heart, and age of the person. In the case of Tongtong, for such as seven \ ^ for adults and Lu, if 6 to 3000 mg / day ^ and is 20 ~ _ (four) 曰 around the amount of 5, - three meals adenine * ☆ ~ Technique and quantity and according to the above examples, the amount of garlic processed or vitamin 6 is determined. There is no special adenosine or its physiological content for the pharmaceutical administration method of the present invention - two kinds of tree protection and the processing of Dalin processing materials, or one dose. In the case where the components are administered at a time of change, it is preferred that 疋' is pre-t with other active ingredients at a time when the blood concentration of the previously administered active ingredient has not decreased. As a method of injecting the medicine of the present invention, it is possible to do the same, and/or to alleviate the fatigue. (4) The point of view... The father is good at the same time: the invention of medicine, can also be applied to mental fatigue caused by physical fatigue, or mental stress such as environmental stress, fatigue or chronic fatigue syndrome (centrality 0, Φ 酉 ,, as shown in the following examples, for the prevention and / or mitigation of physical fatigue and / / /, according to its prevention 122012.doc -17- 200812594 and / or to relieve fatigue, can play Alleviate symptoms such as visual fatigue, muscle waist pain, shoulder stiffness, and general burnout, or 'Zhe: strong, nutritional supplements (for example, body nourishment 1 ' physical fatigue, decreased physical strength after illness, into % vibration, nutritional disorders, The effect of hair growth, such as dysentery, dysentery, pure lactation, etc., physical strength, etc. % [Examples] Hereinafter, the present invention is more specifically limited to the following embodiments by way of examples. Example.

Test Example I The experiment was carried out according to the following method. &lt;Test method&gt; On the first day of the test, a 5-week-old BALB/C system was placed in a 20 cm-diameter water tank of hunger water, and a swimming volume (pre value) was added to the rats.游,,义旦和,大白乳5 is the bell tour W 〆/7 里 is the number of times the white mouse moves to the adjacent and diagonal regions when the water surface of the sink is divided into 4 parts. ^, and then, since the test Zhao will be repeatedly tested for drugs to 4 food. On the 5th day of the test, you will be allowed to swim in the same sink on the 4th night of the test, and the 20-year-old will swim in the same sink. After the swimming, the π-throw and the experimental drug will be placed. 0 minutes, the amount of swimming in 5 minutes was measured in the sample tank &gt; permanent rate of change) #出游PR value) Xl〇〇). In addition, the group of shovel shovel to be tested is compared with the control group (the 物. 5% methyl borax 4 technique and the abbreviation "Μρ, '素 (hereinafter, referred to as MC in the middle of the example)) The amount of swimming (= the experimental drug is administered to the group swimming „ (4) the amount of change in the amount of change). The average swimming of the control group 122012.doc -18- 200812594 using y-adenosine triphosphate (hereinafter, in the examples Abbreviated as "ATP") 120 mg/kg, oxoamidin powder (manufactured by Riken Chemical Industry Co., Ltd.), 50 rng/kg, ATP 120 mg/kg, and oxoamidin powder 50 mg/kg (hereinafter, in the examples) The abbreviation "ATP+oxoamidin powder" as the test drug will be suspended or dissolved in 0.5% f-based cellulose for testing. &lt;Experimental Results&gt; The results are shown in Fig. 1 and Table 1. [Table 1] Test group administration amount (mg/kg) Swimming volume change rate (%) Mean Shi SE Swimming amount relative value Swimming increase amount (%) Meant SE Control group - 44.8 ± 3.6 1.00 - ATP 120 49.4 ± 5.5 1.10 4.6±5·5 oxoamidin powder 50 51.2±5·4 1.14 6.4 soil 5.4 ATP+oxoamidin powder 120+50 1 62·3±4·4* 1.39 17.5+4.4 The relative swimming value is used to indicate the average swimming of the control group. The average swimming rate change rate of each test group when the amount change rate was set to 1.00. The increase in swimming volume indicates the increase in the rate of change in swimming volume of the experimental drug-administered group relative to the control group. N=14~17 * : p&lt;0.05 vs control group (Dimnett type multiple comparison) Judging the synergistic effect using the Bulge method: 1.39 (ATP + oxoamidin powder) &gt; 1 · 1 0 (ATP) x 1 · 14 (oxoamidin Powder) Test Example 2 <Test Method> 122012.doc -19- 200812594 Except for the ATP slave and the amount of 12 〇mg/kg, and the powder dosage of $15 mg/kg, the rest and test Example 1 was carried out in the same manner. The results are shown in Figure 2 and Table 2. [Table 2] Test group administration amount (mg/kg) Swimming volume change rate (%). mean± SE Swimming amount relative value Swimming increase amount (%) mean±SE Control group - 45.314.8 1.00 ATP 120 47.7+10.4 1.05 2·4±10.4 oxoamidin powder 15 47.7±5.8 1.05 2.4±5·8 ATP+oxoamidin powder 120+15 67.5±14.4 1~~1 &quot;1 ' _ 丨丨...—— 1.49 22.2±14.4, in swimming relative The value indicates the average swimming rate change rate of each test group when the average swimming amount change rate of the control group is 1.00. The increase in swimming volume indicates the increase in the rate of change in swimming volume of the experimental drug-administered group relative to the control group. N=7 Use the Fu (four) method to judge the synergy effect:! 49 (Yang + Caga He Powder) &gt; 1 · 05 (ΑΤΡ) χ 1 · 〇 5 (οχ〇αηιί (Ηιι powder) in comparison with the control group administered with Mc, in ATP, gxg (10) _ powder alone A certain increase in the rate of change in swimming volume was found in the group, but it had no significant effect. However, in the drug-administering group (ATP+oxoamidin powder) of the present invention, a significant change in the rate of swimming was found. A significant difference was found in the comparison with the control group administered with MC; in addition, the ratio of the increase in the swimming rate change rate relative to the control group (relative value of swimming amount) was in Test Example 1 in the ATP-following group. 110, in the powder administration group, the product of (3), *, etc. (125) is less than 122012.doc •20· 200812594 AT~—the powder is in Test Example 2, and is 1 in the A” group. In the oxoamidin powder administration group, Xing's Zhiji product (1.10) is less than ΑΤΡ + oxoamidin powder! 49, , straw by Bulge method to draw the following conclusions · · 5,-ATP or its birth ^, human The combination of the salt and the garlic processed product has a synergistic effect in preventing and/or alleviating the fatigue effect. In addition, in the increase in the amount of swimming in the increase in the swimming rate change rate compared with the control group, the pharmaceutical administration group of the present invention can be compared with the individual administration group of Ατρ and coffee at the end. The increase in the rate of change of the swimming ice s. The results show that the medicine of the present invention is used for physical fatigue accompanying exercise load and mental fatigue caused by environmental stress in the water environment, and is used with 51-triphosphate or 1 Wind/, α 甘飞, physiological 孥 allow salt and garlic processing to prevent synergy and/or alleviate fatigue. Manufacturing Example 1 1 曰 quantity (3 tablets) 60.0 mg 5〇·0 mg 12.0 mg 30.0 Mg 50.0 mg 10.0 mg 4.0 mg 10.0 mg 20.7 mg 112.6 mg 25.0 mg 50.0 mg 40.0 mg 24.0 mg 125.7 mg 5 ' - three-disc acid sulphate oxoamidin powder acanthopanax dry extract (native kohlrabi K dry extract (The original drug gf J is 30 〇mg} arginine hydrochloride", Kaili is 240 mg) thiamine nitrate riboflavin hydrochloride dl-α-tocopherol succinic acid about ascorbate in the test of decylamine anhydrous coffee Non-hardened oil hydroxypropyl cellulose knot Cellulose 122012.doc -21 . 200812594 30.0 mg A〇.rry 660.0 mg Carboxymethylcellulose magnesium stearate total 5'-disodium adenosine disodium 48〇g, 〇x〇amidin powder 4〇〇 g, Acanthopanax dry extract 96 g, Astragalus dry extract 24 g, arginine hydrochloride

400 g, thiamine nitrate 8 〇 g, riboflavin 32 g, pyridoxine hydrochloride 8 〇 g, α-tocopherol calcium succinate 165·6 g, sodium ascorbate 9 〇〇·8 g, nicotinic acid amide 2 〇〇g, anhydrous caffeine 400 g, hardened oil 32〇g, hydroxypropyl cellulose 192 g, crystalline cellulose 1〇〇5·6 g, carboxymethyl cellulose 24〇g into a high-speed stirring granulator P〇wrex: FM-VG-25 type) was mixed, and then 600 g of ethanol was added for kneading. The kneaded material was dried using a fluidized bed dryer (Freund Industries: NFLO-5 type), and then granulated using a granulator (Okada Seiko: ND-10S type). 5232 g of the whole granules and 48 g of magnesium stearate were put into a mixer (KOTOBUKI Industrial Co., Ltd.: ΡΜ·5〇) and mixed, and then an ingot machine having a diameter of 8 mm and a curvature radius of 10 mm was installed. Iron Works: 11!^?1888) Obtained 1 tablet of 22〇11^. Production Example 2 1 曰 quantity (3 rotations) 51-Adenosine triphosphate disodium 120.0 mg oxoamidin powder 50.0 mg phenylphosphine thiamine 138.3 mg riboflavin 12.0 mg pyridoxine hydrochloride 50.0 mg cyanocobalamin 60.0 μ§ γ-grass protein (orizanol) 10.0 mg dl-α-tocopherol calcium succinate 103.6 mg D-mannitol 116.0 mg crystalline cellulose 12 0 · 1 mg hydroxypropyl cellulose 37.5 mg 122012.doc -22- 200812594 45.0 mg 7,5 mg Carboxymethyl cellulose calcium 810.0 mg Total stearic acid--W. V / ill ^ 5 bis-diphosphate adenosine disodium 720 g, oxoamidin powder 3 〇〇 g, stupid thiamine 829 _ 8 g, nuclear yellow 72 g, pyridoxine 300 g, γ•grassin g dl α'shengyue jj white acid dance 621 ·6 g, D-mannitol 696 g, crystalline fibrin 720.6 g, hydroxypropyl Cellulose 225 g, carboxymethyl cellulose calcium g is added to the South Speed granulator (Powrex: FM-VG-25 type) to mix one;,, after adding pre-dissolved cyanamide 5 〇〇g of 360 mg of ethanol was carried out in this east and then granulated by a granulator (Okada Seiko: ND-10S type), which was pulverized and granulated using a fluidized layer dryer: nfl〇_5 type) Dry matter, j: In the future, using a granulator (Okada Seiko: (10) type, the whole granule 4815 g, slightly reduced g magnesium stearate 45 g into a mixer (Asahi-day: B2/109 type) Mixed with Bayi °' and then installed with a diameter of 8 · 5 mm, a curved diameter of 12 mm, and a machine with a diameter of 12 mm to obtain a m 270 mg lozenge. 3 1 曰 quantity (6 tablets) of adenosine phosphate disodium oxoamidin powder 60. 〇mg guanidine thiamine hydrochloride 3 〇. 〇mg chondroitin sodium 20.0 mg D-mannitol 900.0 mg crystalline cellulose 125 '〇mg Hydroxypropylcellulose 13 0.0 mg 竣methylcellulose|Bow 40·8 mg Magnesium stearate 61.2 mg Total +~~~----~ -------I^Oms 122012.doc -23 - 200812594 5 g of adenosine diphosphate disodium, 24 g of 〇x〇amidin powder, 80 g of furan sulphate, 36 g of chondroitin sulfate, 5 g of D-mannitol, crystallization 520 g of cellulose, 163. 2 g of hydroxypropylcellulose, and 244.8 g of calcium carboxymethylcellulose were mixed into an idle stirring granulator (p〇wrex LvG-25 type), and then mixed with 900 g of ethanol to carry out kneading. Pulverized granulated with Granulator (Okada Seiko ·· ND-10S type). The granulated product was dried using a fluidized bed dryer (Freund Industries: NFLA5 type), and then granulated using a granulator (Okada Seiko: ND-10S type). 5388 g of the whole granules and 52 g of hard magnesium ruthenate were put into a mixer (Asahi Industries: B2/1〇9 type), and then an ingot machine having a diameter of 8 mm and a curvature radius of 12,111,111 安装 was installed.畑铁工所: HT-AP18SS type) obtained a tablet of ^23〇呵. Production Example 1 1 day amount (3 tablets) 60.0 mg 20.0 mg 180.0 mg 10.0 mg 20.0 mg 10.0 mg 20.0 mg 20.0 pg 20.0 mg 20.0 mg 3 6.0 mg 144.0 mg 24.0 mg 3 0.0 mg 6,0 mg 600.0 mg adenosine triphosphate oxoamidin Powder amaranth extract (converted amount of 600 mg) acetic acid d-α-tocopherol bisbenzoquinone thiamine riboflavin hydrochloride pyridoxine cyanocobalamin calcium pantothenate. Final test amine hardening oil crystalline cellulose hydroxypropyl Cellulose, carboxymethyl cellulose, magnesium stearate _ __ 122012.doc -24- 200812594

5, adenosine triphosphate disodium 480 g, oxoamidin powder 160 g, human cockroach extract 1440 g, acetic acid (1-(1-tocopherol 80 §, bisbenzoquinone thiamine 160 hydroxy, riboflavin 80 g, guanidine hydrochloride) σ polyol 16 0 g, pantothenic acid #5 16 0 g, road test S sulphate 160 g, hardened oil 288 g, crystalline cellulose 1152 g, hydroxypropyl cellulose 192 g, carboxymethyl cellulose calcium 240 g input A high-speed stirring granulator (Powrex: FM-VG-25 type) was mixed, and then 700 g of ethanol dissolved in 160 mg of cyanocobalamin was added for kneading, and then a granulator (Okada Seiko: ND-10S type) was used. The granules were pulverized and dried using a fluidized bed dryer (Freund Industries: NFLO-5 type), and then granulated using a granulator (Okada Seiko: ND-10S type). The granules were 4752 g. , 48 g of magnesium stearate was put into a mixer (KOTOBUKI Technical Industry: PM-50) and mixed, and then an ingot machine with a diameter of 8 mm, a curvature radius of 12 mm and a thickness of 4 mm was installed (畑铁工所: HT -AP18SS type) Obtained 1 tablet of 200 mg tablet. Manufacturing Example 5 1 day (3 spindles) 5'-Adenosine triphosphate 60.0 mg oxoamidin Powder 3 0.0 mg Hydrochloric acid Sulfamethoxazole 100.0 mg pyridoxine hydrochloride 1 00.0 mg mecobalamin (vitamin B 12) 1 5 00 pg acetic acid d-α-tocopherol 100.0 mg hardened oil 3 6.0 mg crystalline cellulose 112.5 mg hydroxypropyl cellulose 24.0 mg Carboxymethyl cellulose calcium 3 0.0 mg Magnesium stearate 6.0 mg Mercaptoacrylic acid copolymer LD 41.0 mg 122012.doc -25 - 200812594 12.3 mg 6.16 mg 0.54 mg Talc powder Triethyl citrate titanium oxide __ Total 660.0 mg 5'-three filled Si: 480 g of adenosine steel, 240 g of oxoamidin powder, 800 g of furan thiamine hydrochloride, 800 g of pyridoxine hydrochloride, 800 g of d-α-tocopherol acetate, 288 g of hardened oil , crystalline cellulose 90〇8, hydroxypropyl cellulose 192 g, carboxymethyl cellulose calcium 240 g was put into a high-speed stirring granulator (Powrex.· FM-VG-25 type) and mixed, and then pre-dissolved with a Cocoamine (mecobalamin) 12 g of ethanol (700 g) was kneaded and pulverized and granulated using a granulator (Okada Seiko: ND-10S type). This was made using a fluidized bed dryer (Freund industry: NFLO-5 type). After the granules are dried, use a granulator (Okada Seiko: ND-10S type) for the whole . The whole granules of 4752 g and 48 g of magnesium stearate were put into a mixer (KOTOBUKI Industrial Co., Ltd.: PM-50) and mixed, and then an ingot machine having a diameter of 8 mm, a curvature radius of 12 mm, and a 4 mm crucible was installed. (畑铁工所: HT-AP18SS type) obtained 1 ingot of 200 mg bare ingot. Using a vented coating machine (Dria Coater DRC-650DS type Powrex Co., Ltd.), 2400 g of purified water, DM 410 g of methacrylic acid copolymer, 123 g of talc, and 61.6 g of triethyl citrate were dissolved and dispersed. A film coating liquid of 5.4 g of titanium oxide was coated on the bare ingot to obtain a film of 220 mg of a film coated ingot. Production Example 6 10.0 mg (3 spindles) 60.0 mg 20.0 mg 5'-Adenosine triphosphate disodium oxoamidin powder 122012.doc -26- 200812594 Hazelnut extract 60.0 mg Rabbit silk extract 3.0 mg Royal jelly 50.0 mg Dehydrocholic acid 10.0 mg riboflavin 10.0 mg cyanocobalamin 2.0 pg acetic acid da-fertility@分10.0 mg in proguanamine 12.0 mg anhydrous caffeine 5 0.0 mg hardened oil 3 6.0 mg D-mannitol 93.0 mg crystalline cellulose 120.0 mg hydroxypropyl Cellulose 24.0 mg Carboxymethylcellulose 36.0 mg Magnesium stearate 6.0 Me Total 600.0 mg

511 g of 51-trisodium citrate, 160 g of oxoamidin powder, 480 g of hazelnut extract, 24 g of rabbit silk extract, 400 g of royal jelly, 80 g of dehydrocholic acid, 80 g of riboflavin, Sour acid d-α-fertility 80 g, proguanamine 96 g, anhydrous caffeine 400 g, hardened oil 288 g, D-mannitol 744 g, crystalline cellulose 960 g, hydroxypropyl cellulose 192 g, 288 g of carboxymethylcellulose was put into a high-speed spoiler (Powrex: FM-VG-25 type) and mixed, and then 600 g of ethanol dissolved in 12 mg of cyanocobalamin in advance was added for kneading. The kneaded product was dried using a fluidized bed dryer (Freund lean: NFLO-5 type), and then granulated using a granulator (Okada Seiko: ND-10S type). The whole granules of 4752 g and 48 g of magnesium stearate were put into a mixer (KOTOBUKI Industrial Co., Ltd.: PM-50) and mixed, and then an ingot machine (barium iron) having a diameter of 8 mm and a curvature radius of 12 mm was installed. Workplace: HT-AP18SS type) Obtain 1 tablet of 200 mg tablets. Production Example 7 122012.doc -27- 200812594 1曰(6 spindles) 5'-adenosine triphosphate 60.0 mg oxoamidin powder 200.0 mg placenta extract 800.0 mg thiamine nitrate (vitamin B1) 10.0 mg acetic acid d- Α-tocopherol 10.0 mg Human extract 60.0 mg Hardened oil 64.0 mg D-mannose pass 120.0 mg Crystalline cellulose 155.0 mg Calcium citrate 48.0 mg Hydroxypropyl cellulose. 60.0 mg Carboxymethyl cellulose calcium 84.0 mg Steaester Magnesium sulphate 9.0 ms Total 1680.0 mg 5'-Tribasic acid adenine 180 g, oxoamidin powder 600 g, placental extract 24 〇 0 g, thiamine nitrate 30 g, acetic acid d-α-tocopherol 30 g, Human extract 180 g, hardened oil 192 g, D-mannitol 360 g, crystalline cellulose 465 g, calcium citrate 144 g, hydroxypropyl cellulose 18 〇 g 'carboxymethyl fiber Fen Ma 252 g into high speed A mixing granulator (p〇wrex: FM-VG-25 type) was mixed, and then 700 g of ethanol was added for kneading, and further pulverized and granulated using a granulator (Okada Seiko: NEMOS type). After the granules were dried using a fluidized bed dryer (Freund Industries: NFLO-5 type), the granule granulator (Okada Seiko: ND-10S type) was granulated. The whole granules of 4815 g and 27 g of magnesium stearate were put into a mixer (Asahi Industries: β2/1〇9 type), and then iron ingots with a diameter of 9 mm and a curvature radius of 155 mm were installed. Works: HT-AP18SS type) Obtained Us28〇mgi lozenge. Production Example 8 1 曰 quantity (2 spindles) 122012.doc -28 - 200812594 5'- glyphosate triphosphate 120.0 mg oxoamidin powder 5 0.0 mg thiamine nitrate 30.0 mg riboflavin 4.0 mg sterol hydrochloride 24.0 mg Cyanocobalamin 60.0 pg Hardening oil 24.0 mg Crystalline fiber 100.0 mg Hydroxypropyl cellulose 20.0 mg Carboxymethyl vegan calcium 24.0 mg Magnesium stearate 4.0 mg Total 400.0 mg

1440 g of 5f-Adipic diphosphate, 600 g of oxoamidin powder, 360 g of thiamine nitrate, 48 g of riboflavin, 288 g of pyridoxine hydrochloride, 288 g of hardened oil, 1200 g of crystalline cellulose, hydroxypropyl 240 g of cellulose and 288 g of calcium carboxymethylcellulose were mixed in a high-speed stirring granulator (Powrex: FM-VG-25 type), and then mixed with 600 g of ethanol having 720 mg of cyanogenamide dissolved in advance. The kneaded product was dried using a fluidized bed dryer (Freund Industries: NFLO-5 type), and then granulated using a granulator (Okada Seiko: ND-10S type). The whole granules of 4752 g and 48 g of magnesium stearate were put into a mixer (KOTOBUKI Industrial Co., Ltd.: PM-50) and mixed, and then an ingot machine with a diameter of 8 mm and a radius of curvature of 14 mm was installed. Workplace: HT-八? 1888 type) Obtain a tablet of 20 〇 111 §. Production Example 9 1 day amount (3 spindles) 5'-ADP disodium 60.0 mg oxoamidin powder 50.0 mg arginine hydrochloride 50.0 mg γ-grass protein 10.0 mg 122012.doc -29- 200812594 Thiamine nitrate 10.0 mg nucleus 4.04.0 mg pyridoxine hydrochloride 10.0 mg dl-a-tocopherol calcium succinate 20.7 mg palmitate acid network 2000.0 IU anti-sodium sulphate 112.6 mg sulphate 25.0 mg anhydrous caffeine 50.0 mg hardened oil 100.9 mg Crystalline cellulose 165.6 rag hydroxypropyl cellulose 3 7.5 mg carboxymethyl cellulose dian 65.0 mg stearyl magnesium 7.5 mg total 780.0 mg 5 - 2 disc acid gland disodium 360 g, oxoamidin powder 300 g, hydrochloric acid Amino acid 300 g, sputum protein 6 〇 g, thiamine nitrate (iv) g, riboflavin % g, pyridoxine hydrochloride 6 〇 g ' dl-a • tocopherol calcium succinate 124.2 g, ascorbic acid 酉 纳 6 7 5.6 g, private test guanamine 1 5 G g, anhydrous caffeine 3 〇〇 g, hardened oil 605.4 g, crystalline cellulose 993·6 g, hydroxypropyl cellulose 225 邑, carboxymethyl cellulose calcium 390 g It is put into a high-speed stirring granulator (P〇wrex: FM-VG-25 type) and mixed, and then pre-dispersed with palmitic acid. Retinol 7.2 ^ 600 g of ethanol, kneaded, further using granulator (Okada Seiko · n ⑽ type) pulverized granulated. The granulated product was dried using a fluidized bed dryer (F_d industry: NFLO-5 type), and then granulated using a granulator (Okada Seiko: ND-10S type). The tablet of the whole granules of 4635 g, hard acid acetonitrile, and a radius of curvature of 12 匪杵 (畑铁 m AP18SSS) was obtained into a tablet of 26 〇mg. [Simplified illustration] 122012.doc -30- 200812594 Figure 1 shows the ATP 120 mg/kg, oxoamidiri powder 50 mg/kg, and the increase in swimming (%) of the combined use group. Fig. 2 is a graph showing the ATP 120 mg/kg, the oxoamidin powder 15 mg/kg, and the swimming increase (%) of the combined use group. Ο 122012.doc -31 -

Claims (1)

200812594 X. The scope of application for patents: i. A kind of prevention and/or alleviation of fatigue. #甘商药's system will make 5'-tris-adenosine into its physiologically acceptable salt and big 荇 ★ t Λ, The combination of knowledge and work. 2. The medicine of item 1 wherein the medicine contains a form of a pharmaceutical composition of &amp; adenosine triphosphate or a physiologically acceptable salt thereof and a garlic processed product. 3. As requested in the medicine, the pot, and then contains vitamins selected from vitamins, vitamins, vitamins and vitamins &amp; More than one type of vitamins. The medical treatment of any of the items 1 to 3 is based on physical fatigue and or mental fatigue. 5. The medicine according to any one of items i to 3, wherein the garlic processing system is processing garlic 〇 6. The medicine of any one of the items i to 3, the central adenosine triphosphate or its physiological substance The combination ratio of the salt and the garlic processed product is: a processed large cup as a converted amount, and the garlic processed material is 0·1 to 2 parts by mass with respect to 5,-triphosphate adenosine or its physiologically acceptable summer/shellfish injury. 122012.doc 200812594 VII. Designated representative map: (1) The representative representative of the case is: (1). (2) A brief description of the symbol of the representative figure: (No description of the symbol of the component) 10 VIII. If there is a chemical formula in this case, please disclose the chemical formula that best shows the characteristics of the invention: (none) 122012.doc